Drug Type Small molecule drug |
Synonyms LY 3381916, LY3381916 |
Target |
Mechanism IDO1 inhibitors(Indoleamine 2,3-dioxygenase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H25FN2O3 |
InChIKeyNUBWFWVVKLRSHS-OAHLLOKOSA-N |
CAS Registry2166616-75-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 1 | US | 17 Nov 2017 | |
Non-Small Cell Lung Cancer | Phase 1 | BE | 17 Nov 2017 | |
Non-Small Cell Lung Cancer | Phase 1 | DK | 17 Nov 2017 | |
Non-Small Cell Lung Cancer | Phase 1 | FR | 17 Nov 2017 | |
Non-Small Cell Lung Cancer | Phase 1 | IT | 17 Nov 2017 | |
Non-Small Cell Lung Cancer | Phase 1 | ES | 17 Nov 2017 | |
Renal Cell Carcinoma | Phase 1 | US | 17 Nov 2017 | |
Renal Cell Carcinoma | Phase 1 | BE | 17 Nov 2017 | |
Renal Cell Carcinoma | Phase 1 | DK | 17 Nov 2017 | |
Renal Cell Carcinoma | Phase 1 | FR | 17 Nov 2017 |
NCT03343613 (ESMO2019) Manual | Phase 1 | 42 | hpndzbevss(bvjrzveqne) = 3 pts (1 pt, Part A 240mg BID with Grade 3 [Gr] ALT/AST increase and systemic inflammatory response syndrome; 2 pts, Part B 240mg QD with Gr 3 fatigue and Gr 3 immunerelated hepatitis) qwkvdluprn (ubqvfnhqpc ) View more | Positive | 01 Dec 2019 |